EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Aminopyridines Restore Ventilation and Reverse Respiratory Acidosis at Late Stages of Botulism in Mice

William T McClintic iD, Zachary D Chandler, Lalitha M Karchalla, Celinia A Ondeck, Sean W O'Brien, Charity J Campbell, Alan R Jacobson, Patrick M McNutt iD

The Journal of Pharmacology and Experimental Therapeutics · 2024

DOI: 10.1124/jpet.123.001773 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2024. Verfasst von William T McClintic und 7 weiteren Autor:innen. Beteiligte Einrichtung: Wake Forest Institute for Regenerative Medicine, Wake Forest University Health Sciences, Winston-Salem, North Carolina. Hauptthemen laut MEDLINE: Botulism, Acidosis, Respiratory, Botulinum Toxins, Type A. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Botulinum neurotoxin (BoNT) is a potent protein toxin that causes muscle paralysis and death by asphyxiation. Treatments for symptomatic botulism are intubation and supportive care until respiratory function recovers. Aminopyridines have recently emerged as potential treatments for botulism. The clinically approved drug 3,4-diaminopyridine (3,4-DAP) rapidly reverses toxic signs of botulism and has antidotal effects when continuously administered in rodent models of lethal botulism. Although the therapeutic effects of 3,4-DAP likely result from the reversal of diaphragm paralysis, the corresponding effects on respiratory physiology are not understood. Here, we combined unrestrained whole-body plethysmography (UWBP) with arterial blood gas measurements to study the effects of 3,4-DAP, and other aminopyridines, on ventilation and respiration at terminal stages of botulism in mice. Treatment with clinically relevant doses of 3,4-DAP restored ventilation in a dose-dependent manner, producing significant improvements in ventilatory parameters within 10 minutes. Concomitant with improved ventilation, 3,4-DAP treatment reversed botulism-induced respiratory acidosis, restoring blood levels of CO2, pH, and lactate to normal physiologic levels. Having established that 3,4-DAP-mediated improvements in ventilation were directly correlated with improved respiration, we used UWBP to quantitatively evaluate nine additional aminopyridines in BoNT/A-intoxicated mice. Multiple aminopyridines were identified with comparable or enhanced therapeutic efficacies compared with 3,4-DAP, including aminopyridines that selectively improved tidal volume versus respiratory rate and vice versa. In addition to contributing to a growing body of evidence supporting the use of aminopyridines to treat clinical botulism, these data lay the groundwork for the development of aminopyridine derivatives with improved pharmacological properties. SIGNIFICANCE STATEMENT: There is a critical need for fast-acting treatments to reverse respiratory paralysis in patients with botulism. This study used unrestrained, whole-body plethysmography and arterial blood gas analysis to show that aminopyridines rapidly restore ventilation and respiration and reverse respiratory acidosis when administered to mice at terminal stages of botulism. In addition to supporting the use of aminopyridines as first-line treatments for botulism symptoms, these data are expected to contribute to the development of new aminopyridine derivatives with improved pharmacological properties.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BotulismAcidosis, RespiratoryBotulinum Toxins, Type AMiceHumansAnimalsAminopyridinesAmifampridineParalysisRespiration

Substanzen

AminopyridinesAmifampridineBotulinum Toxins, Type A

Autor:innen und Institutionen

  • Wake Forest Institute for Regenerative Medicine, Wake Forest University Health Sciences, Winston-Salem, North Carolina.
  • Wake Forest Institute for Regenerative Medicine, Wake Forest University Health Sciences, Winston-Salem, North Carolina pmcnutt@wakehealth.edu.

ORCID-Profile: William T McClintic, Patrick M McNutt

Förderung

  • NIAID NIH HHS

Zitieren

APA

McClintic, W. T., Chandler, Z. D., Karchalla, L. M., Ondeck, C. A., O'Brien, S. W., Campbell, C. J., Jacobson, A. R., & McNutt, P. M. (2024). Aminopyridines Restore Ventilation and Reverse Respiratory Acidosis at Late Stages of Botulism in Mice. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.123.001773

Vancouver

McClintic WT, Chandler ZD, Karchalla LM, Ondeck CA, O'Brien SW, Campbell CJ, et al. Aminopyridines Restore Ventilation and Reverse Respiratory Acidosis at Late Stages of Botulism in Mice. The Journal of Pharmacology and Experimental Therapeutics. 2024. doi:10.1124/jpet.123.001773

BibTeX
@article{McClintic2024,
  author = {McClintic, William T and Chandler, Zachary D and Karchalla, Lalitha M and Ondeck, Celinia A and O'Brien, Sean W and Campbell, Charity J and Jacobson, Alan R and McNutt, Patrick M},
  title = {Aminopyridines Restore Ventilation and Reverse Respiratory Acidosis at Late Stages of Botulism in Mice},
  journal = {The Journal of Pharmacology and Experimental Therapeutics},
  year = {2024},
  doi = {10.1124/jpet.123.001773}
}
Kostenlos starten →